Stockreport

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Zenas BioPharma, Inc.  (ZBIO) 
PDF - Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x Fc?RIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multip [Read more]